Our friends at the FDA Law Blog have a quality summary this afternoon of the U.S. Supreme Court’s denial of review in two cases involving the use of the Federal False Claims Act in the context of off-label “promotion.”  The Court denied cert to Hopper v. Solvay Pharms, Inc. and United States, ex rel. Mark Eugene Duxbury v. Ortho Biotech Products, L.P.  WLF filed an amicus brief in support of Ortho Biotech’s petition, and also recently published a paper on off-label case defendants’ efforts to dismiss False Claims Act suits where both cases were examined.